These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 11991964)

  • 1. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
    Chakrabarti BK; Kong WP; Wu BY; Yang ZY; Friborg J; Ling X; King SR; Montefiori DC; Nabel GJ
    J Virol; 2002 Jun; 76(11):5357-68. PubMed ID: 11991964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
    Khattar SK; Samal S; LaBranche CC; Montefiori DC; Collins PL; Samal SK
    PLoS One; 2013; 8(10):e78521. PubMed ID: 24098600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunogenicity of plasmid DNA and adenoviral vectors encoding HIV-1 subtype B env gene].
    Yang HR; Zhang LF; Feng X; Yu SQ; Zhuang ZL; Li HX; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Dec; 24(6):415-7. PubMed ID: 21604562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
    Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
    J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
    Bolesta E; Kowalczyk A; Wierzbicki A; Eppolito C; Kaneko Y; Takiguchi M; Stamatatos L; Shrikant PA; Kozbor D
    J Immunol; 2006 Jul; 177(1):177-91. PubMed ID: 16785513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
    Sailaja G; Husain S; Nayak BP; Jabbar AM
    J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
    Beddows S; Franti M; Dey AK; Kirschner M; Iyer SP; Fisch DC; Ketas T; Yuste E; Desrosiers RC; Klasse PJ; Maddon PJ; Olson WC; Moore JP
    Virology; 2007 Apr; 360(2):329-40. PubMed ID: 17126869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.
    Doria-Rose NA; Learn GH; Rodrigo AG; Nickle DC; Li F; Mahalanabis M; Hensel MT; McLaughlin S; Edmonson PF; Montefiori D; Barnett SW; Haigwood NL; Mullins JI
    J Virol; 2005 Sep; 79(17):11214-24. PubMed ID: 16103173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan.
    Bolmstedt A; Hinkula J; Rowcliffe E; Biller M; Wahren B; Olofsson S
    Vaccine; 2001 Nov; 20(3-4):397-405. PubMed ID: 11672902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.
    Khattar SK; DeVico AL; LaBranche CC; Panda A; Montefiori DC; Samal SK
    J Virol; 2016 Feb; 90(3):1682-6. PubMed ID: 26581986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV env immunities elicited by nucleic acid vaccines.
    Shiver JW; Davies ME; Yasutomi Y; Perry HC; Freed DC; Letvin NL; Liu MA
    Vaccine; 1997 Jun; 15(8):884-7. PubMed ID: 9234539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.